Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when NKTR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsNektar Therapeutics reports Q1 2026 financial results
Filed May 7, 2026 · Period ending May 7, 2026 · ~1 min read
Key Changes
-
high
Nektar announced first quarter 2026 financial results via press release on May 7, 2026. Actual revenue, earnings, cash position, and pipeline updates are in the attached press release, not the 8-K itself.
Item 2.02 verify on EDGAR → -
medium
This is a standard quarterly earnings disclosure. Investors should review the full press release (Exhibit 99.1) for financial details and any forward guidance provided by management.
8-K: Earnings view on EDGAR →
Summary
Nektar Therapeutics filed an 8-K to formally notify the SEC that it released first quarter 2026 financial results on May 7, 2026. The filing itself is procedural—it contains no financial figures, only a reference to the press release attached as Exhibit 99.1. This is the standard mechanism biotech companies use to disclose quarterly performance.
Retail investors should review the full press release for key metrics: revenue from any partnered programs, operating expenses, cash runway, and updates on clinical pipeline progress. For a clinical-stage biotech like Nektar, cash position and trial milestones often matter more than quarterly revenue. Watch for any changes to development timelines or partnership terms in the press release, as these can materially affect the company's valuation and ability to fund operations through key data readouts.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 7, 2026, Nektar Therapeutics, a Delaware corporation (“Nektar”), issued a press release (the “Press Release”) announcing its financial results for the quarter ended March 31, 2026.
Nektar disclosed its first quarter 2026 financial results through a press release. The 8-K itself does not contain the actual financial figures — those are in the attached press release (Exhibit 99.1). This filing serves as the formal notification to the SEC that results were publicly announced.
Event · Item 9.01 — Financial Statements and Exhibits
Nektar Therapeutics filed an 8-K attaching its Q1 2026 earnings press release.
Added in current filing · verify on EDGAR →
Press release titled “Nektar Therapeutics Reports First Quarter 2026 Results.”
Nektar disclosed its first quarter 2026 financial results via press release attached as Exhibit 99.1. The 8-K itself contains no financial details; investors must review the press release for revenue, earnings, cash position, pipeline updates, and guidance. This is a standard quarterly earnings disclosure mechanism.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify